These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 33628239)

  • 1. Role of Dynamic Susceptibility Contrast Perfusion MRI in Glioma Progression Evaluation.
    Quan G; Zhang K; Liu Y; Ren JL; Huang D; Wang W; Yuan T
    J Oncol; 2021; 2021():1696387. PubMed ID: 33628239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma.
    Boxerman JL; Ellingson BM; Jeyapalan S; Elinzano H; Harris RJ; Rogg JM; Pope WB; Safran H
    Am J Clin Oncol; 2017 Jun; 40(3):228-234. PubMed ID: 25436828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diffusion kurtosis imaging combined with dynamic susceptibility contrast-enhanced MRI in differentiating high-grade glioma recurrence from pseudoprogression.
    Shi W; Qu C; Wang X; Liang X; Tan Y; Zhang H
    Eur J Radiol; 2021 Nov; 144():109941. PubMed ID: 34735828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study.
    Gahramanov S; Raslan AM; Muldoon LL; Hamilton BE; Rooney WD; Varallyay CG; Njus JM; Haluska M; Neuwelt EA
    Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):514-23. PubMed ID: 20395065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic Accuracy of Arterial Spin Labeling in Comparison With Dynamic Susceptibility Contrast-Enhanced Perfusion for Brain Tumor Surveillance at 3T MRI.
    Lavrova A; Teunissen WHT; Warnert EAH; van den Bent M; Smits M
    Front Oncol; 2022; 12():849657. PubMed ID: 35669426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of clinically available dynamic susceptibility contrast post processing software to differentiate progression from pseudoprogression in post-treatment high grade glioma.
    Nierobisch N; Ludovichetti R; Kadali K; Fierstra J; Hüllner M; Michels L; Achangwa NR; Alcaide-Leon P; Weller M; Kulcsar Z; Hainc N
    Eur J Radiol; 2023 Oct; 167():111076. PubMed ID: 37666072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applying amide proton transfer-weighted MRI to distinguish pseudoprogression from true progression in malignant gliomas.
    Ma B; Blakeley JO; Hong X; Zhang H; Jiang S; Blair L; Zhang Y; Heo HY; Zhang M; van Zijl PC; Zhou J
    J Magn Reson Imaging; 2016 Aug; 44(2):456-62. PubMed ID: 26788865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging for glioma grading: Preliminary comparison of vessel compartment and permeability parameters using hotspot and histogram analysis.
    Santarosa C; Castellano A; Conte GM; Cadioli M; Iadanza A; Terreni MR; Franzin A; Bello L; Caulo M; Falini A; Anzalone N
    Eur J Radiol; 2016 Jun; 85(6):1147-56. PubMed ID: 27161065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging.
    Choi YJ; Kim HS; Jahng GH; Kim SJ; Suh DC
    Acta Radiol; 2013 May; 54(4):448-54. PubMed ID: 23592805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiparametric MRI in differentiating solitary brain metastasis from high-grade glioma: diagnostic value of the combined use of diffusion-weighted imaging, dynamic susceptibility contrast imaging, and magnetic resonance spectroscopy parameters.
    Aslan K; Gunbey HP; Tomak L; Incesu L
    Neurol Neurochir Pol; 2019; 53(3):227-237. PubMed ID: 31180131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic Values of DCE-MRI and DSC-MRI for Differentiation Between High-grade and Low-grade Gliomas: A Comprehensive Meta-analysis.
    Liang J; Liu D; Gao P; Zhang D; Chen H; Shi C; Luo L
    Acad Radiol; 2018 Mar; 25(3):338-348. PubMed ID: 29223713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative percentage signal intensity recovery of perfusion metrics—an efficient tool for differentiating grades of glioma.
    Smitha KA; Gupta AK; Jayasree RS
    Br J Radiol; 2015 Aug; 88(1052):20140784. PubMed ID: 26110202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the hypervascularized fraction of glioblastomas using a volume analysis of dynamic susceptibility contrast-enhanced MRI may help to identify pseudoprogression.
    Roques M; Catalaa I; Raveneau M; Attal J; Siegfried A; Darcourt J; Cognard C; de Champfleur NM; Bonneville F
    PLoS One; 2022; 17(10):e0270216. PubMed ID: 36227862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differentiation of progressive disease from pseudoprogression using 3D PCASL and DSC perfusion MRI in patients with glioblastoma.
    Manning P; Daghighi S; Rajaratnam MK; Parthiban S; Bahrami N; Dale AM; Bolar D; Piccioni DE; McDonald CR; Farid N
    J Neurooncol; 2020 May; 147(3):681-690. PubMed ID: 32239431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic Susceptibility Perfusion Imaging for Differentiating Progressive Disease from Pseudoprogression in Diffuse Glioma Molecular Subtypes.
    Richter V; Klose U; Bender B; Rabehl K; Skardelly M; Schittenhelm J; Tabatabai G; Hempel JM; Ernemann U; Brendle C
    J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33562558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of single-dose, dual-echo based CBV threshold for fractional tumor burden mapping in recurrent glioblastoma.
    Anil A; Stokes AM; Chao R; Hu LS; Alhilali L; Karis JP; Bell LC; Quarles CC
    Front Oncol; 2023; 13():1046629. PubMed ID: 36733305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentiation between intra-axial metastatic tumor progression and radiation injury following fractionated radiation therapy or stereotactic radiosurgery using MR spectroscopy, perfusion MR imaging or volume progression modeling.
    Huang J; Wang AM; Shetty A; Maitz AH; Yan D; Doyle D; Richey K; Park S; Pieper DR; Chen PY; Grills IS
    Magn Reson Imaging; 2011 Sep; 29(7):993-1001. PubMed ID: 21571478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-dimensional arterial spin labeling imaging and dynamic susceptibility contrast perfusion-weighted imaging value in diagnosing glioma grade prior to surgery.
    Ma H; Wang Z; Xu K; Shao Z; Yang C; Xu P; Liu X; Hu C; Lu X; Rong Y
    Exp Ther Med; 2017 Jun; 13(6):2691-2698. PubMed ID: 28587332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebral blood flow changes after radiation therapy identifies pseudoprogression in diffuse intrinsic pontine gliomas.
    Calmon R; Puget S; Varlet P; Dangouloff-Ros V; Blauwblomme T; Beccaria K; Grevent D; Sainte-Rose C; Castel D; Debily MA; Dufour C; Bolle S; Dhermain F; Saitovitch A; Zilbovicius M; Brunelle F; Grill J; Boddaert N
    Neuro Oncol; 2018 Jun; 20(7):994-1002. PubMed ID: 29244086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment monitoring in gliomas: comparison of dynamic susceptibility-weighted contrast-enhanced and spectroscopic MRI techniques for identifying treatment failure.
    Vöglein J; Tüttenberg J; Weimer M; Gerigk L; Kauczor HU; Essig M; Weber MA
    Invest Radiol; 2011 Jun; 46(6):390-400. PubMed ID: 21285888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.